

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/573,962
Filing Date	March 29, 2006
First Named Inventor	Dimitrov et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	251149
DHHS Reference No.	E-316-2003/0-US-03

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
	A A	2003-0147881	A1	Cheung et al.	Aug. 7, 2003	
	A B	2003-0018004	A1	Kingsman et al.		
	A C	2003-0133939	A1	Ledbetter et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code		Yes	No**
	A D	WO	02/093519	A2	Heintges, et al.	Nov. 21, 2002	+
	A E	WO	03/033866	A2	Dimitrov et al.	April 24, 2003	
	A F	WO	03/095492	A1	Dimitrov et al.	Nov. 20, 2003	

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A G	CHENG et al., "Construction, Expression and Characterization of the Engineered Antibody Against Tumor Surface Antigen," <i>Cell Research</i> , 13(1): 35-48 (2003)		
	A H	DALGLEISH et al., "The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus," <i>Nature</i> , 312: 763-767 (1984);		
	A I	DIMITROV, D.S., "Cell Biology of Virus Entry," <i>Cell</i> , 101(7): 697-702 (2000)		
	A J	DIMITROV, D.S., "Fusin - a place for HIV-1 and T4 Cells to Meet. The Identification of the Long Sought Coreceptor Mediating HIV-1 Entry Raises New Hopes for AIDS Prevention and Treatment," <i>Nature Med.</i> , 2: 640-641 (1996)		
	A K	KLATZMANN et al., "T-lymphocyte T4 Molecule Behaves as the Receptor for Human Retrovirus LAV" <i>Nature</i> , 312: 767-768 (1984)		
	A L	LABRIJN ARAN F. et al. "Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1", <i>Journal of Virology</i> , 77 (19): 10557-10565 (Oct. 2003)		
	A M	MOORE et al., "Probing the Structure of the V2 Domain of Human Immunodeficiency Virus Type 1 Surface Glycoprotein gp120 with a Panel of Eight Monoclonal Antibodies: Human Immune Response to the V1 and V2 Domains", <i>Journal of Virology</i> , 67 (10): 6136-6151 (1993)		

Examiner Signature _____ Date Considered _____

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.90(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/573,952	
			Filing Date	March 29, 2006	
			First Named Inventor	Dimitrov et al.	
			Group Art Unit	Unassigned	
			Examiner Name	Unassigned	
			Attorney Docket Number	251149	
Sheet	2	of	3	DHHS Reference No.	E-316-2003/0-US-03

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A N	MOULARD M. et al. "Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes", <i>Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, D.C.</i> , 99 (10): 6913-6918 (05-14-2002)		
	A O	MYERS et al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-specific scFv Fusion Proteins," <i>Cancer Gene Therapy</i> , 9: 884-896 (2002)		
	A P	PARREN et al., "The Antiviral Activity of Antibodies <i>In Vitro</i> and <i>In Vivo</i> " <i>Advances in Immunology</i> , 77: 195-262 (2001)		
	A Q	PARREN et al., "Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity" <i>Journal of Virology</i> , 72 (5): 3512-3519 (1998)		
	A R	RAY et al., "Selection of Single Chain Variable Fragments (scFv) Against the Glycoprotein Antigen of the Rabies Virus from a Human Synthetic scFv Phage Display Library and their Fusion with the Fc Region of Human IgG1," <i>Clin. Exp. Immunol.</i> 125: 94-101 (2001)		
	A S	RIZZUTO et al., "Fine Definition of a Conserved CCR5-Binding Region on the Human Immunodeficiency Virus Type 1 Glycoprotein 120," <i>AIDS Res. Hum. Retrovir.</i> , 16 (8): 741-749 (2000)		
	A T	RIZZUTO et al., "A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding" <i>Science</i> , 280: 1949-1953 (1998)		
	A U	SATTENTAU et al., "Conformational Changes Induced in the Human Immunodeficiency Virus Envelope Glycoprotein by Soluble CD4 Binding," <i>J. Exp. Med.</i> , 174: 407-415 (1991)		
	A V	SATTENTAU et al., "Conformational Changes Induced in the Envelope Glycoproteins of the Human and Simian Immunodeficiency Viruses by Soluble Receptor Binding," <i>Journal of Virology</i> , 67 (12w): 7383-7393 (1993)		
	A W	THALI et al., "Characterization of Conserved Human Immunodeficiency Virus Type 1 gp120 Neutralization Epitopes Exposed upon gp120-CD4 Binding" <i>Journal of Virology</i> , 67 (7): 3978-3988 (1993)		
	A X	TRKOLA et al., "Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp120 Glycoprotein of Human Immunodeficiency Virus Type 1," <i>Journal of Virology</i> , 70(2): 1100-1108 (1996)		
	A Y	TRKOLA et al., "CD-4 Dependent, Antibody-Sensitive Interactions Between HIV-1 and its Co-Receptor CCR-5," <i>Nature</i> , 384: 184-187 (1996)		
	A Z	UGOLINI et al., "Inhibition of Virus Attachment to CD4 Target Cells is a Major Mechanism of T Cell Line-adapted HIV-1 Neutralization" <i>J. Exp. Med.</i> , 186 (8): 1287-1298 (1997)		
	B A	WU et al., "CD4-Induced Interaction of Primary HIV-1 gp120 Glycoproteins with the Chemokine Receptor CCR-5" <i>Nature</i> , 384: 179-183 (1996)		
	B B	WU et al., "Multimerization of a Chimeric Anti-CD20 Single-Chain Fv-Fc Fusion Protein is Mediated Through Variable Domain Exchange," <i>Protein Engineering</i> , 14(12): 1025-1033 (2001)		

Examiner Signature	Date Considered
--------------------	-----------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/P/O				Complete if Known Application Number 10/573,952 Filing Date March 29, 2006 First Named Inventor Dimitrov et al. Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 251149 DHHS Reference No. E-316-2003/0-US-03	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	3	of	3		

[illegible]

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

- * A concise statement of relevance is being submitted in lieu of a translation, or English-language version, of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise statement of relevance under 37 CFR 1.98(a)(3).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/